Esperion Therapeutics stock remains a buy as strong drug franchises, growth, and global milestones outweigh risks. Learn more ...

Possibly the most absurd truth of modern computing is that, as far as the technology has evolved, we're fundamentally still doing the exact same thing we were doing decades ago: twiddling bits. The ...

Givaudan has a strong competitive moat, solid profitability, and a healthy balance sheet. It also finally appears reasonably ...

On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...

Enterprises today are equipped with a vast array of tools and technologies. The opportunity lies in bringing these ...

Cloud And AI Growth Under Scrutiny​.) ​​​Pivotal moment for strategic transformation ​Alibaba is expected to report its ...

Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) has been the odd one out in the Magnificent Seven for a while. The stock didn’t make parabolic gains, whereas most other AI stocks were on a rally that was truly ...

This week, the government shutdown entered its fifth week and, on Nov. 4, 2025, became the longest in history, beating a 34-day-plus record set ...

The Early tier ($25 per month) has monthly limits of 20 invoices and five bills. The Growing plan ($55 per month) supports ...

Decide between three patterns – streamed desktops (VDI/DaaS), per‑app access via ZTNA and application proxies, and local ...